+

WO2001039796A3 - Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides - Google Patents

Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides Download PDF

Info

Publication number
WO2001039796A3
WO2001039796A3 PCT/CA2000/001413 CA0001413W WO0139796A3 WO 2001039796 A3 WO2001039796 A3 WO 2001039796A3 CA 0001413 W CA0001413 W CA 0001413W WO 0139796 A3 WO0139796 A3 WO 0139796A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
prevention
treatment
vaccine
related diseases
Prior art date
Application number
PCT/CA2000/001413
Other languages
English (en)
Other versions
WO2001039796A2 (fr
Inventor
Robert Chalifour
Lise Hebert
Xianqi Kong
Francine Gervais
Original Assignee
Neurochem Inc
Robert Chalifour
Lise Hebert
Xianqi Kong
Francine Gervais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU18473/01A priority Critical patent/AU784312B2/en
Priority to BR0016022-9A priority patent/BR0016022A/pt
Priority to JP2001541528A priority patent/JP2004500354A/ja
Priority to MXPA02005576A priority patent/MXPA02005576A/es
Priority to EP00981111A priority patent/EP1235587A2/fr
Priority to IL14992400A priority patent/IL149924A0/xx
Application filed by Neurochem Inc, Robert Chalifour, Lise Hebert, Xianqi Kong, Francine Gervais filed Critical Neurochem Inc
Priority to CA002388559A priority patent/CA2388559A1/fr
Priority to KR1020027006845A priority patent/KR20020073341A/ko
Publication of WO2001039796A2 publication Critical patent/WO2001039796A2/fr
Publication of WO2001039796A3 publication Critical patent/WO2001039796A3/fr
Priority to NO20022531A priority patent/NO20022531L/no
Priority to HK03100407.4A priority patent/HK1049279A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un vaccin à antigène « non-soi » à base stéréochimique, destiné à la prévention et/ou au traitement de la maladie d'Alzheimer et d'autres maladies associées aux substances amyloïdes. Le vaccin destiné à la prévention et/ou au traitement de la maladie d'Alzheimer et d'autres maladies associées aux substances amyloïdes selon cette invention surmonte les inconvénients associés à l'utilisation de peptides, de protéines et d'immunogènes naturels.
PCT/CA2000/001413 1999-11-29 2000-11-29 Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides WO2001039796A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR0016022-9A BR0016022A (pt) 1999-11-29 2000-11-29 Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
JP2001541528A JP2004500354A (ja) 1999-11-29 2000-11-29 全ｄ体ペプチドを含む、アルツハイマー病およびアミロイド関連疾患の予防および処置のためのワクチン
MXPA02005576A MXPA02005576A (es) 1999-11-29 2000-11-29 Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
EP00981111A EP1235587A2 (fr) 1999-11-29 2000-11-29 Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides
IL14992400A IL149924A0 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU18473/01A AU784312B2 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CA002388559A CA2388559A1 (fr) 1999-11-29 2000-11-29 Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides
KR1020027006845A KR20020073341A (ko) 1999-11-29 2000-11-29 알츠하이머 및 아밀로이드 관련 질병의 예방 및 치료용 백신
NO20022531A NO20022531L (no) 1999-11-29 2002-05-28 Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
HK03100407.4A HK1049279A1 (zh) 1999-11-29 2003-01-16 預防及治療阿爾茨海默病(早老性痴呆)及澱粉樣蛋白有關的病之疫苗

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16859499P 1999-11-29 1999-11-29
US60/168,594 1999-11-29
US72484200A 2000-11-28 2000-11-28
US09/724,842 2000-11-28

Publications (2)

Publication Number Publication Date
WO2001039796A2 WO2001039796A2 (fr) 2001-06-07
WO2001039796A3 true WO2001039796A3 (fr) 2001-12-06

Family

ID=26864284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001413 WO2001039796A2 (fr) 1999-11-29 2000-11-29 Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides

Country Status (13)

Country Link
EP (1) EP1235587A2 (fr)
JP (1) JP2004500354A (fr)
KR (2) KR20020073341A (fr)
CN (1) CN1433321A (fr)
AU (1) AU784312B2 (fr)
BR (1) BR0016022A (fr)
CA (1) CA2388559A1 (fr)
HK (1) HK1049279A1 (fr)
IL (1) IL149924A0 (fr)
MX (1) MXPA02005576A (fr)
NO (1) NO20022531L (fr)
NZ (1) NZ540564A (fr)
WO (1) WO2001039796A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (fr) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE FIXANT LA SEQUENCE KLVFF DE L'AMYLOIDE $g(b)
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CZ20022748A3 (cs) * 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
AU2007200047B2 (en) * 2000-07-07 2009-11-26 Bioarctic Neuroscience Ab Prevention and treatment of Alzheimer's disease
WO2002003911A2 (fr) 2000-07-07 2002-01-17 Lars Lannfelt Prevention et traitement de la maladie d'alzheimer
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004005318A2 (fr) 2002-07-03 2004-01-15 Bio Science International, Inc. Peptides comprenant des aminoacides d aromatiques et leurs methodes d'utilisation
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP2007516938A (ja) * 2003-06-23 2007-06-28 ニューロケム （インターナショナル） リミテッド アミロイド関連疾患を治療するための方法および組成物
PT2336147E (pt) * 2003-12-17 2014-07-16 Janssen Alzheimer Immunotherap Conjugados transportadores de péptidos beta imunogénicos e seus processos de produção
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (fr) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
KR100851035B1 (ko) 2005-08-23 2008-08-11 대한민국 ＧＣＰ-Ⅱ를 유효성분으로 함유하는 β-아밀로이드의 뇌내축적 예방 및 치료용 약학적 조성물과 치료제 스크리닝용조성물 및 이를 이용한 스크리닝 방법
US8067372B2 (en) 2005-11-10 2011-11-29 Alzheimer's Institute Of America, Inc. Modulation of angiogenesis by A-beta peptide fragments
KR101434935B1 (ko) 2005-11-30 2014-10-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도
EP1959991B1 (fr) * 2005-12-12 2013-03-20 AC Immune S.A. Vaccin therapeutique
JO2824B1 (en) 2005-12-12 2014-09-15 اف . هوفمان لاروش ايه جي Antibody glycosylate in the changing region
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2468770B1 (fr) 2006-07-14 2017-12-20 AC Immune S.A. Anticorps humanisés contre beta amyloide.
TW201815827A (zh) * 2006-07-14 2018-05-01 瑞士商Ａｃ免疫公司 抗β-類澱粉抗體或其抗原結合片段、其用途及使用方法
ES2640095T3 (es) * 2006-10-02 2017-10-31 Ac Immune S.A. Anticuerpo humanizado contra beta-amiloide
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2655868T3 (es) 2007-04-20 2018-02-22 The Chemo-Sero-Therapeutic Research Institute Método para aumentar la respuesta inmunitaria con un péptido
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009143489A2 (fr) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation d’angiogenèse par des fragments de peptide a-bêta
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2273273A1 (fr) * 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibiteurs de la nitration de peptides ß amyloïdes et leurs utilisations pour le diagnostic et le traitement de la maladie d'Alzheimer
EP2603524A1 (fr) 2010-08-14 2013-06-19 AbbVie Inc. Protéines de liaison bêta-amyloïdes
MA53887A (fr) 2014-07-10 2021-10-27 Bioarctic Ab Anticorps à liaison protofibrille a-bêta améliorée
EP3313879B1 (fr) 2015-06-24 2022-01-05 F. Hoffmann-La Roche AG Anticorps du récepteur anti-transferrine avec affinité sur mesure
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AU2016333512B2 (en) 2015-10-02 2022-11-17 F. Hoffmann-La Roche Ag Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
JP7448174B2 (ja) * 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
AU2017299858B2 (en) 2016-07-18 2024-07-25 Promis Neurosciences, Inc. Antibodies to Amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (fr) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de peptides beta-amyloides, comprenant des d-aminoacides
WO1999058564A1 (fr) * 1998-05-08 1999-11-18 Norsk Hydro Asa Mutants de dephasage de proteine de precurseur de beta-amyloide et d'ubiquitine-b et leur utilisation
WO2000068263A2 (fr) * 1999-05-05 2000-11-16 Neurochem, Inc. Peptides stereoselectifs antifibrillogenese et peptidomimetiques correspondants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (fr) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de peptides beta-amyloides, comprenant des d-aminoacides
WO1999058564A1 (fr) * 1998-05-08 1999-11-18 Norsk Hydro Asa Mutants de dephasage de proteine de precurseur de beta-amyloide et d'ubiquitine-b et leur utilisation
WO2000068263A2 (fr) * 1999-05-05 2000-11-16 Neurochem, Inc. Peptides stereoselectifs antifibrillogenese et peptidomimetiques correspondants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENKIRANE NADIA ET AL: "Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues: Antibodies to a D-enantiomer do recognize the parent L-hexapeptide and reciprocally.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 35, 1993, pages 26279 - 26285, XP002164690, ISSN: 0021-9258 *
VAN REGENMORTEL M H ET AL: "D - peptides as immunogens and diagnostic reagents.", CURRENT OPINION IN BIOTECHNOLOGY, (1998 AUG) 9 (4) 377-82. REF: 37, XP000990989 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
WO2001039796A2 (fr) 2001-06-07
AU784312B2 (en) 2006-03-09
NZ540564A (en) 2007-04-27
CN1433321A (zh) 2003-07-30
EP1235587A2 (fr) 2002-09-04
AU1847301A (en) 2001-06-12
CA2388559A1 (fr) 2001-06-07
KR20020073341A (ko) 2002-09-23
HK1049279A1 (zh) 2003-05-09
IL149924A0 (en) 2002-11-10
BR0016022A (pt) 2002-08-06
KR20080059676A (ko) 2008-06-30
JP2004500354A (ja) 2004-01-08
NO20022531L (no) 2002-07-12
MXPA02005576A (es) 2002-12-13
NO20022531D0 (no) 2002-05-28

Similar Documents

Publication Publication Date Title
WO2001039796A3 (fr) Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides
WO2002096937A3 (fr) Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees au substances amyloides
WO2000072876A3 (fr) Prevention et traitement de maladies amyloidogenes
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
EP2258383A3 (fr) Peptides antigènes dérivés de la télomérase
EP1918300A3 (fr) Thérapie d'immunisation à base de peptide pour le traitement d'athérosclérose
WO2003020764A3 (fr) Facteur ix modifie
WO2005087261A3 (fr) Identification d'antigenes autologues ou non autologues impliques dans des maladies auto-immunes
WO2000078344A8 (fr) Peptides proteiniques du prion et utilisations associees
WO2000076540A3 (fr) Proteines et vaccins de streptococcus pneumoniae
IL163812A (en) Immunizing composition, antigenic product and isolated antigenic peptide for inducing an immune response against beta-secretase cleavage site of amyloid the precursor protein
WO2001058485A3 (fr) Anticorps monoclonaux a vocation prophylactique et therapeutique
WO2000018351A3 (fr) Produits aglyco et utilisation de ceux-ci
WO2002059143A3 (fr) Peptides therapeutiques pour troubles de la demyelinisation
WO2001053457A3 (fr) Vaccins contre certains troubles neurodegeneratifs
PL371278A1 (en) Modified factor viii
WO2001014395A3 (fr) Nouveaux glycoconjuges et acides glycoamino leurs intermediaires et leurs utilisations
WO2002058725A3 (fr) Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2001058470A3 (fr) Procedes permettant d'ameliorer la biodisponibilite d'un medicament
WO2003055440A8 (fr) Compositions et methodes de traitement de maladies d'origine immune
WO2002070004A3 (fr) Immunogenes et vaccins ainsi que leur preparation et leur utilisation
MXPA04004970A (es) Epitopos de linfocitos t en carboxipeptidasa g2.
WO2001066740A3 (fr) Compositions et methodes de traitement de maladies d'origine immune
WO2002074332A3 (fr) Procede d'amelioration de l'immunogenicite d'un antigene
WO2003074003A3 (fr) Immunogenes destines au traitement de maladies malignes et infectieuses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2002 200201317

Country of ref document: RO

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2388559

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 18473/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 519117

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2001 541528

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 149924

Country of ref document: IL

Ref document number: 1020027006845

Country of ref document: KR

Ref document number: 008164142

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005576

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000981111

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000981111

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027006845

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载